AbbVie claims that Genmab divulged key trade secrets to support the development of ProfoundBio’s investigational ...

Innovent Biologics has dosed the first subject in the Phase III HeriCare-Ovarian01 trial of IBI354 for treating PROC with ...

Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...

Puxitatug samrotecan (P-Sam), an investigational antibody-drug conjugate (ADC) targeting B7-H4-expressing tumors, showed ...

Scientists at Charles University and Mayo Foundation for Medical Education and Research (MFMER) have synthesized DNA topoisomerase II β inhibitors reported to be useful for the treatment of ...

An oral dose of zoliflodacin – vying to become the first in the new class of bacterial type II topoisomerase inhibitors – was found to be as effective as the standard regimen of injectable ...

Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors Identification, Synthesis, and Biological ...

(NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an ...